[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f8NBqlIM3zzV1CNDbXAGeE6wfQvLPIZpzUQt4_0bnQjM":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":32,"phaseBuckets":43,"rows":50},"Johann Wolfgang Goethe University Hospital",[4],159,false,5,10,1183347,3,128,[14,17,19,21,24,26,28,30],{"name":15,"count":16},"Heart Failure",6,{"name":18,"count":16},"Ataxia Telangiectasia",{"name":20,"count":8},"Allergic Asthma",{"name":22,"count":23},"Bronchiolitis Obliterans",4,{"name":25,"count":23},"Coronary Artery Disease",{"name":27,"count":11},"Asthma",{"name":29,"count":11},"House Dust Mite Allergy",{"name":31,"count":11},"Anemia",[33,38],{"nctId":34,"briefTitle":35,"date":36,"intervention":37},"NCT03369210","Liberal Transfusion Strategy in Elderly Patients","2025-06-30","red blood cell transfusion trigger",{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT03383978","Intracranial Injection of NK-92\u002F5.28.z Cells in Combination With Intravenous Ezabenlimab in Patients With Recurrent HER2-positive Glioblastoma","2027-12-31","NK-92\u002F5.28.z",[44,45,46,47,48,49],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[51,77,101,119,210,248,278,304,339,365,391,417,443,469,492,514,536,558,580,606,624,642,660,678,696,714,736,759,777,795,813,839,868,902,927,953,976,1000,1018,1042,1067,1093,1111,1129,1147,1165,1183,1201,1219,1237,1261,1286,1309,1334,1352,1370,1388,1412,1440,1468,1486,1513],{"intervention":37,"totalTrials":52,"cells":53},1,{"EARLY_PHASE1":54,"PHASE1":57,"PHASE2":59,"PHASE3":61,"PHASE4":73,"NA":75},{"trials":55,"activeCount":56},[],0,{"trials":58,"activeCount":56},[],{"trials":60,"activeCount":56},[],{"trials":62,"activeCount":52,"soonestReadout":36},[63],{"nctId":34,"briefTitle":35,"status":64,"phases":65,"primaryCompletion":36,"completion":66,"start":67,"enrollment":68,"conditions":69,"interventions":72},"ACTIVE_NOT_RECRUITING",[47],"2026-07-31","2017-12-04",2470,[70,71,31],"Transfusion-dependent Anemia","Surgery",[37],{"trials":74,"activeCount":56},[],{"trials":76,"activeCount":56},[],{"intervention":42,"totalTrials":52,"cells":78},{"EARLY_PHASE1":79,"PHASE1":81,"PHASE2":93,"PHASE3":95,"PHASE4":97,"NA":99},{"trials":80,"activeCount":56},[],{"trials":82,"activeCount":52,"soonestReadout":41},[83],{"nctId":39,"briefTitle":40,"status":84,"phases":85,"primaryCompletion":41,"completion":86,"start":87,"enrollment":88,"conditions":89,"interventions":91},"RECRUITING",[45],"2028-06-30","2017-12-01",42,[90],"Glioblastoma",[42,92],"Ezabenlimab",{"trials":94,"activeCount":56},[],{"trials":96,"activeCount":56},[],{"trials":98,"activeCount":56},[],{"trials":100,"activeCount":56},[],{"intervention":92,"totalTrials":52,"cells":102},{"EARLY_PHASE1":103,"PHASE1":105,"PHASE2":111,"PHASE3":113,"PHASE4":115,"NA":117},{"trials":104,"activeCount":56},[],{"trials":106,"activeCount":52,"soonestReadout":41},[107],{"nctId":39,"briefTitle":40,"status":84,"phases":108,"primaryCompletion":41,"completion":86,"start":87,"enrollment":88,"conditions":109,"interventions":110},[45],[90],[42,92],{"trials":112,"activeCount":56},[],{"trials":114,"activeCount":56},[],{"trials":116,"activeCount":56},[],{"trials":118,"activeCount":56},[],{"intervention":120,"totalTrials":23,"cells":121},"cyclophosphamide",{"EARLY_PHASE1":122,"PHASE1":124,"PHASE2":126,"PHASE3":167,"PHASE4":169,"NA":208},{"trials":123,"activeCount":56},[],{"trials":125,"activeCount":56},[],{"trials":127,"activeCount":56},[128,153],{"nctId":129,"briefTitle":130,"status":131,"phases":132,"start":133,"conditions":134,"interventions":136},"NCT00002531","Combination Chemotherapy in Treating Adults With Acute Lymphocytic Leukemia","UNKNOWN",[46],"1993-01",[135],"Leukemia",[137,120,138,139,140,141,142,143,144,145,146,147,148,149,150,151,152],"asparaginase","cytarabine","daunorubicin hydrochloride","dexamethasone","doxorubicin hydrochloride","etoposide","ifosfamide","leucovorin calcium","mercaptopurine","methotrexate","mitoxantrone hydrochloride","prednisolone","teniposide","thioguanine","vincristine sulfate","vindesine",{"nctId":154,"briefTitle":155,"status":131,"phases":156,"start":157,"conditions":158,"interventions":161},"NCT00199186","Study Comparing Imatinib With Chemotherapy as Induction in Elderly Patients With Philadelphia Positive Acute Lymphoblastic Leukemia (ALL)",[46],"2002-03",[159,160],"Philadelphia Positive Acute Lymphoblastic Leukemia","Lymphoid Blastic Phase of Chronic Myeloid Leukemia",[162,163,120,164,140,165,146,166,140],"imatinib","vincristine","cytosine arabinoside","idarubicin","AraC",{"trials":168,"activeCount":56},[],{"trials":170,"activeCount":56},[171,197],{"nctId":172,"briefTitle":173,"status":174,"phases":175,"primaryCompletion":176,"completion":176,"start":177,"enrollment":178,"conditions":179,"interventions":181},"NCT00199004","Trial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and Rituximab","COMPLETED",[48],"2009-03","2004-04",60,[180],"Adult Acute Lymphocytic Leukemia",[182,183,184,185,186,187,188,189,190,191,192,193,194,195,196],"Cyclophosphamide","Dexamethasone \u002F Prednisolone","Vincristine","Daunorubicin","Asparaginase","Methotrexate","Cytarabine","Mercaptopurine","G-CSF","Vindesine","VP16","Adriamycin","Thioguanine","VM26","Rituximab",{"nctId":198,"briefTitle":199,"status":174,"phases":200,"primaryCompletion":176,"start":177,"enrollment":201,"conditions":202,"interventions":204},"NCT00199017","German Multicenter Trial for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults",[48],75,[203],"Lymphoma, Lymphoblastic",[205,182,184,185,186,190,189,188,187,192,191,193,194,206,207],"Dexamethasone\u002FPrednisolone","HDARAC","Cladribine",{"trials":209,"activeCount":56},[],{"intervention":188,"totalTrials":23,"cells":211},{"EARLY_PHASE1":212,"PHASE1":214,"PHASE2":216,"PHASE3":222,"PHASE4":224,"NA":246},{"trials":213,"activeCount":56},[],{"trials":215,"activeCount":56},[],{"trials":217,"activeCount":56},[218],{"nctId":129,"briefTitle":130,"status":131,"phases":219,"start":133,"conditions":220,"interventions":221},[46],[135],[137,120,138,139,140,141,142,143,144,145,146,147,148,149,150,151,152],{"trials":223,"activeCount":56},[],{"trials":225,"activeCount":56},[226,238,242],{"nctId":227,"briefTitle":228,"status":131,"phases":229,"start":230,"enrollment":231,"conditions":232,"interventions":234},"NCT00199147","Efficacy of G-CSF-Priming in Elderly AML Patients",[48],"2000-01",250,[233],"Acute Myeloid Leukemia",[188,235,236,190,237],"Etoposide","Idarubicin","Fludarabine",{"nctId":172,"briefTitle":173,"status":174,"phases":239,"primaryCompletion":176,"completion":176,"start":177,"enrollment":178,"conditions":240,"interventions":241},[48],[180],[182,183,184,185,186,187,188,189,190,191,192,193,194,195,196],{"nctId":198,"briefTitle":199,"status":174,"phases":243,"primaryCompletion":176,"start":177,"enrollment":201,"conditions":244,"interventions":245},[48],[203],[205,182,184,185,186,190,189,188,187,192,191,193,194,206,207],{"trials":247,"activeCount":56},[],{"intervention":146,"totalTrials":23,"cells":249},{"EARLY_PHASE1":250,"PHASE1":252,"PHASE2":254,"PHASE3":264,"PHASE4":266,"NA":276},{"trials":251,"activeCount":56},[],{"trials":253,"activeCount":56},[],{"trials":255,"activeCount":56},[256,260],{"nctId":129,"briefTitle":130,"status":131,"phases":257,"start":133,"conditions":258,"interventions":259},[46],[135],[137,120,138,139,140,141,142,143,144,145,146,147,148,149,150,151,152],{"nctId":154,"briefTitle":155,"status":131,"phases":261,"start":157,"conditions":262,"interventions":263},[46],[159,160],[162,163,120,164,140,165,146,166,140],{"trials":265,"activeCount":56},[],{"trials":267,"activeCount":56},[268,272],{"nctId":172,"briefTitle":173,"status":174,"phases":269,"primaryCompletion":176,"completion":176,"start":177,"enrollment":178,"conditions":270,"interventions":271},[48],[180],[182,183,184,185,186,187,188,189,190,191,192,193,194,195,196],{"nctId":198,"briefTitle":199,"status":174,"phases":273,"primaryCompletion":176,"start":177,"enrollment":201,"conditions":274,"interventions":275},[48],[203],[205,182,184,185,186,190,189,188,187,192,191,193,194,206,207],{"trials":277,"activeCount":56},[],{"intervention":186,"totalTrials":11,"cells":279},{"EARLY_PHASE1":280,"PHASE1":282,"PHASE2":284,"PHASE3":290,"PHASE4":292,"NA":302},{"trials":281,"activeCount":56},[],{"trials":283,"activeCount":56},[],{"trials":285,"activeCount":56},[286],{"nctId":129,"briefTitle":130,"status":131,"phases":287,"start":133,"conditions":288,"interventions":289},[46],[135],[137,120,138,139,140,141,142,143,144,145,146,147,148,149,150,151,152],{"trials":291,"activeCount":56},[],{"trials":293,"activeCount":56},[294,298],{"nctId":172,"briefTitle":173,"status":174,"phases":295,"primaryCompletion":176,"completion":176,"start":177,"enrollment":178,"conditions":296,"interventions":297},[48],[180],[182,183,184,185,186,187,188,189,190,191,192,193,194,195,196],{"nctId":198,"briefTitle":199,"status":174,"phases":299,"primaryCompletion":176,"start":177,"enrollment":201,"conditions":300,"interventions":301},[48],[203],[205,182,184,185,186,190,189,188,187,192,191,193,194,206,207],{"trials":303,"activeCount":56},[],{"intervention":140,"totalTrials":11,"cells":305},{"EARLY_PHASE1":306,"PHASE1":308,"PHASE2":310,"PHASE3":320,"PHASE4":322,"NA":337},{"trials":307,"activeCount":56},[],{"trials":309,"activeCount":56},[],{"trials":311,"activeCount":56},[312,316],{"nctId":129,"briefTitle":130,"status":131,"phases":313,"start":133,"conditions":314,"interventions":315},[46],[135],[137,120,138,139,140,141,142,143,144,145,146,147,148,149,150,151,152],{"nctId":154,"briefTitle":155,"status":131,"phases":317,"start":157,"conditions":318,"interventions":319},[46],[159,160],[162,163,120,164,140,165,146,166,140],{"trials":321,"activeCount":56},[],{"trials":323,"activeCount":56},[324],{"nctId":325,"briefTitle":326,"status":174,"phases":327,"primaryCompletion":328,"completion":329,"start":330,"enrollment":331,"conditions":332,"interventions":334},"NCT00805649","Combined Therapy in Age-Related Macular Degeneration (ARMD)",[48],"2008-06","2008-07","2006-01",150,[333],"Age-Related Macular Degeneration",[140,335,336],"bevacizumab","triamcincolone",{"trials":338,"activeCount":56},[],{"intervention":189,"totalTrials":11,"cells":340},{"EARLY_PHASE1":341,"PHASE1":343,"PHASE2":345,"PHASE3":351,"PHASE4":353,"NA":363},{"trials":342,"activeCount":56},[],{"trials":344,"activeCount":56},[],{"trials":346,"activeCount":56},[347],{"nctId":129,"briefTitle":130,"status":131,"phases":348,"start":133,"conditions":349,"interventions":350},[46],[135],[137,120,138,139,140,141,142,143,144,145,146,147,148,149,150,151,152],{"trials":352,"activeCount":56},[],{"trials":354,"activeCount":56},[355,359],{"nctId":172,"briefTitle":173,"status":174,"phases":356,"primaryCompletion":176,"completion":176,"start":177,"enrollment":178,"conditions":357,"interventions":358},[48],[180],[182,183,184,185,186,187,188,189,190,191,192,193,194,195,196],{"nctId":198,"briefTitle":199,"status":174,"phases":360,"primaryCompletion":176,"start":177,"enrollment":201,"conditions":361,"interventions":362},[48],[203],[205,182,184,185,186,190,189,188,187,192,191,193,194,206,207],{"trials":364,"activeCount":56},[],{"intervention":194,"totalTrials":11,"cells":366},{"EARLY_PHASE1":367,"PHASE1":369,"PHASE2":371,"PHASE3":377,"PHASE4":379,"NA":389},{"trials":368,"activeCount":56},[],{"trials":370,"activeCount":56},[],{"trials":372,"activeCount":56},[373],{"nctId":129,"briefTitle":130,"status":131,"phases":374,"start":133,"conditions":375,"interventions":376},[46],[135],[137,120,138,139,140,141,142,143,144,145,146,147,148,149,150,151,152],{"trials":378,"activeCount":56},[],{"trials":380,"activeCount":56},[381,385],{"nctId":172,"briefTitle":173,"status":174,"phases":382,"primaryCompletion":176,"completion":176,"start":177,"enrollment":178,"conditions":383,"interventions":384},[48],[180],[182,183,184,185,186,187,188,189,190,191,192,193,194,195,196],{"nctId":198,"briefTitle":199,"status":174,"phases":386,"primaryCompletion":176,"start":177,"enrollment":201,"conditions":387,"interventions":388},[48],[203],[205,182,184,185,186,190,189,188,187,192,191,193,194,206,207],{"trials":390,"activeCount":56},[],{"intervention":191,"totalTrials":11,"cells":392},{"EARLY_PHASE1":393,"PHASE1":395,"PHASE2":397,"PHASE3":403,"PHASE4":405,"NA":415},{"trials":394,"activeCount":56},[],{"trials":396,"activeCount":56},[],{"trials":398,"activeCount":56},[399],{"nctId":129,"briefTitle":130,"status":131,"phases":400,"start":133,"conditions":401,"interventions":402},[46],[135],[137,120,138,139,140,141,142,143,144,145,146,147,148,149,150,151,152],{"trials":404,"activeCount":56},[],{"trials":406,"activeCount":56},[407,411],{"nctId":172,"briefTitle":173,"status":174,"phases":408,"primaryCompletion":176,"completion":176,"start":177,"enrollment":178,"conditions":409,"interventions":410},[48],[180],[182,183,184,185,186,187,188,189,190,191,192,193,194,195,196],{"nctId":198,"briefTitle":199,"status":174,"phases":412,"primaryCompletion":176,"start":177,"enrollment":201,"conditions":413,"interventions":414},[48],[203],[205,182,184,185,186,190,189,188,187,192,191,193,194,206,207],{"trials":416,"activeCount":56},[],{"intervention":190,"totalTrials":11,"cells":418},{"EARLY_PHASE1":419,"PHASE1":421,"PHASE2":423,"PHASE3":425,"PHASE4":427,"NA":441},{"trials":420,"activeCount":56},[],{"trials":422,"activeCount":56},[],{"trials":424,"activeCount":56},[],{"trials":426,"activeCount":56},[],{"trials":428,"activeCount":56},[429,433,437],{"nctId":227,"briefTitle":228,"status":131,"phases":430,"start":230,"enrollment":231,"conditions":431,"interventions":432},[48],[233],[188,235,236,190,237],{"nctId":172,"briefTitle":173,"status":174,"phases":434,"primaryCompletion":176,"completion":176,"start":177,"enrollment":178,"conditions":435,"interventions":436},[48],[180],[182,183,184,185,186,187,188,189,190,191,192,193,194,195,196],{"nctId":198,"briefTitle":199,"status":174,"phases":438,"primaryCompletion":176,"start":177,"enrollment":201,"conditions":439,"interventions":440},[48],[203],[205,182,184,185,186,190,189,188,187,192,191,193,194,206,207],{"trials":442,"activeCount":56},[],{"intervention":184,"totalTrials":11,"cells":444},{"EARLY_PHASE1":445,"PHASE1":447,"PHASE2":449,"PHASE3":455,"PHASE4":457,"NA":467},{"trials":446,"activeCount":56},[],{"trials":448,"activeCount":56},[],{"trials":450,"activeCount":56},[451],{"nctId":154,"briefTitle":155,"status":131,"phases":452,"start":157,"conditions":453,"interventions":454},[46],[159,160],[162,163,120,164,140,165,146,166,140],{"trials":456,"activeCount":56},[],{"trials":458,"activeCount":56},[459,463],{"nctId":172,"briefTitle":173,"status":174,"phases":460,"primaryCompletion":176,"completion":176,"start":177,"enrollment":178,"conditions":461,"interventions":462},[48],[180],[182,183,184,185,186,187,188,189,190,191,192,193,194,195,196],{"nctId":198,"briefTitle":199,"status":174,"phases":464,"primaryCompletion":176,"start":177,"enrollment":201,"conditions":465,"interventions":466},[48],[203],[205,182,184,185,186,190,189,188,187,192,191,193,194,206,207],{"trials":468,"activeCount":56},[],{"intervention":142,"totalTrials":470,"cells":471},2,{"EARLY_PHASE1":472,"PHASE1":474,"PHASE2":476,"PHASE3":482,"PHASE4":484,"NA":490},{"trials":473,"activeCount":56},[],{"trials":475,"activeCount":56},[],{"trials":477,"activeCount":56},[478],{"nctId":129,"briefTitle":130,"status":131,"phases":479,"start":133,"conditions":480,"interventions":481},[46],[135],[137,120,138,139,140,141,142,143,144,145,146,147,148,149,150,151,152],{"trials":483,"activeCount":56},[],{"trials":485,"activeCount":56},[486],{"nctId":227,"briefTitle":228,"status":131,"phases":487,"start":230,"enrollment":231,"conditions":488,"interventions":489},[48],[233],[188,235,236,190,237],{"trials":491,"activeCount":56},[],{"intervention":236,"totalTrials":470,"cells":493},{"EARLY_PHASE1":494,"PHASE1":496,"PHASE2":498,"PHASE3":504,"PHASE4":506,"NA":512},{"trials":495,"activeCount":56},[],{"trials":497,"activeCount":56},[],{"trials":499,"activeCount":56},[500],{"nctId":154,"briefTitle":155,"status":131,"phases":501,"start":157,"conditions":502,"interventions":503},[46],[159,160],[162,163,120,164,140,165,146,166,140],{"trials":505,"activeCount":56},[],{"trials":507,"activeCount":56},[508],{"nctId":227,"briefTitle":228,"status":131,"phases":509,"start":230,"enrollment":231,"conditions":510,"interventions":511},[48],[233],[188,235,236,190,237],{"trials":513,"activeCount":56},[],{"intervention":185,"totalTrials":470,"cells":515},{"EARLY_PHASE1":516,"PHASE1":518,"PHASE2":520,"PHASE3":522,"PHASE4":524,"NA":534},{"trials":517,"activeCount":56},[],{"trials":519,"activeCount":56},[],{"trials":521,"activeCount":56},[],{"trials":523,"activeCount":56},[],{"trials":525,"activeCount":56},[526,530],{"nctId":172,"briefTitle":173,"status":174,"phases":527,"primaryCompletion":176,"completion":176,"start":177,"enrollment":178,"conditions":528,"interventions":529},[48],[180],[182,183,184,185,186,187,188,189,190,191,192,193,194,195,196],{"nctId":198,"briefTitle":199,"status":174,"phases":531,"primaryCompletion":176,"start":177,"enrollment":201,"conditions":532,"interventions":533},[48],[203],[205,182,184,185,186,190,189,188,187,192,191,193,194,206,207],{"trials":535,"activeCount":56},[],{"intervention":192,"totalTrials":470,"cells":537},{"EARLY_PHASE1":538,"PHASE1":540,"PHASE2":542,"PHASE3":544,"PHASE4":546,"NA":556},{"trials":539,"activeCount":56},[],{"trials":541,"activeCount":56},[],{"trials":543,"activeCount":56},[],{"trials":545,"activeCount":56},[],{"trials":547,"activeCount":56},[548,552],{"nctId":172,"briefTitle":173,"status":174,"phases":549,"primaryCompletion":176,"completion":176,"start":177,"enrollment":178,"conditions":550,"interventions":551},[48],[180],[182,183,184,185,186,187,188,189,190,191,192,193,194,195,196],{"nctId":198,"briefTitle":199,"status":174,"phases":553,"primaryCompletion":176,"start":177,"enrollment":201,"conditions":554,"interventions":555},[48],[203],[205,182,184,185,186,190,189,188,187,192,191,193,194,206,207],{"trials":557,"activeCount":56},[],{"intervention":193,"totalTrials":470,"cells":559},{"EARLY_PHASE1":560,"PHASE1":562,"PHASE2":564,"PHASE3":566,"PHASE4":568,"NA":578},{"trials":561,"activeCount":56},[],{"trials":563,"activeCount":56},[],{"trials":565,"activeCount":56},[],{"trials":567,"activeCount":56},[],{"trials":569,"activeCount":56},[570,574],{"nctId":172,"briefTitle":173,"status":174,"phases":571,"primaryCompletion":176,"completion":176,"start":177,"enrollment":178,"conditions":572,"interventions":573},[48],[180],[182,183,184,185,186,187,188,189,190,191,192,193,194,195,196],{"nctId":198,"briefTitle":199,"status":174,"phases":575,"primaryCompletion":176,"start":177,"enrollment":201,"conditions":576,"interventions":577},[48],[203],[205,182,184,185,186,190,189,188,187,192,191,193,194,206,207],{"trials":579,"activeCount":56},[],{"intervention":581,"totalTrials":52,"cells":582},"prevenar",{"EARLY_PHASE1":583,"PHASE1":585,"PHASE2":587,"PHASE3":589,"PHASE4":591,"NA":604},{"trials":584,"activeCount":56},[],{"trials":586,"activeCount":56},[],{"trials":588,"activeCount":56},[],{"trials":590,"activeCount":56},[],{"trials":592,"activeCount":56},[593],{"nctId":594,"briefTitle":595,"status":174,"phases":596,"primaryCompletion":597,"completion":598,"start":599,"enrollment":600,"conditions":601,"interventions":602},"NCT00836641","Safety and Immunogenicity of Sequential Pneumococcal Immunization in Preschool Asthmatics",[48],"2008-10","2008-12","2006-10",70,[27],[581,603],"pneumovax",{"trials":605,"activeCount":56},[],{"intervention":603,"totalTrials":52,"cells":607},{"EARLY_PHASE1":608,"PHASE1":610,"PHASE2":612,"PHASE3":614,"PHASE4":616,"NA":622},{"trials":609,"activeCount":56},[],{"trials":611,"activeCount":56},[],{"trials":613,"activeCount":56},[],{"trials":615,"activeCount":56},[],{"trials":617,"activeCount":56},[618],{"nctId":594,"briefTitle":595,"status":174,"phases":619,"primaryCompletion":597,"completion":598,"start":599,"enrollment":600,"conditions":620,"interventions":621},[48],[27],[581,603],{"trials":623,"activeCount":56},[],{"intervention":336,"totalTrials":52,"cells":625},{"EARLY_PHASE1":626,"PHASE1":628,"PHASE2":630,"PHASE3":632,"PHASE4":634,"NA":640},{"trials":627,"activeCount":56},[],{"trials":629,"activeCount":56},[],{"trials":631,"activeCount":56},[],{"trials":633,"activeCount":56},[],{"trials":635,"activeCount":56},[636],{"nctId":325,"briefTitle":326,"status":174,"phases":637,"primaryCompletion":328,"completion":329,"start":330,"enrollment":331,"conditions":638,"interventions":639},[48],[333],[140,335,336],{"trials":641,"activeCount":56},[],{"intervention":237,"totalTrials":52,"cells":643},{"EARLY_PHASE1":644,"PHASE1":646,"PHASE2":648,"PHASE3":650,"PHASE4":652,"NA":658},{"trials":645,"activeCount":56},[],{"trials":647,"activeCount":56},[],{"trials":649,"activeCount":56},[],{"trials":651,"activeCount":56},[],{"trials":653,"activeCount":56},[654],{"nctId":227,"briefTitle":228,"status":131,"phases":655,"start":230,"enrollment":231,"conditions":656,"interventions":657},[48],[233],[188,235,236,190,237],{"trials":659,"activeCount":56},[],{"intervention":183,"totalTrials":52,"cells":661},{"EARLY_PHASE1":662,"PHASE1":664,"PHASE2":666,"PHASE3":668,"PHASE4":670,"NA":676},{"trials":663,"activeCount":56},[],{"trials":665,"activeCount":56},[],{"trials":667,"activeCount":56},[],{"trials":669,"activeCount":56},[],{"trials":671,"activeCount":56},[672],{"nctId":172,"briefTitle":173,"status":174,"phases":673,"primaryCompletion":176,"completion":176,"start":177,"enrollment":178,"conditions":674,"interventions":675},[48],[180],[182,183,184,185,186,187,188,189,190,191,192,193,194,195,196],{"trials":677,"activeCount":56},[],{"intervention":195,"totalTrials":52,"cells":679},{"EARLY_PHASE1":680,"PHASE1":682,"PHASE2":684,"PHASE3":686,"PHASE4":688,"NA":694},{"trials":681,"activeCount":56},[],{"trials":683,"activeCount":56},[],{"trials":685,"activeCount":56},[],{"trials":687,"activeCount":56},[],{"trials":689,"activeCount":56},[690],{"nctId":172,"briefTitle":173,"status":174,"phases":691,"primaryCompletion":176,"completion":176,"start":177,"enrollment":178,"conditions":692,"interventions":693},[48],[180],[182,183,184,185,186,187,188,189,190,191,192,193,194,195,196],{"trials":695,"activeCount":56},[],{"intervention":196,"totalTrials":52,"cells":697},{"EARLY_PHASE1":698,"PHASE1":700,"PHASE2":702,"PHASE3":704,"PHASE4":706,"NA":712},{"trials":699,"activeCount":56},[],{"trials":701,"activeCount":56},[],{"trials":703,"activeCount":56},[],{"trials":705,"activeCount":56},[],{"trials":707,"activeCount":56},[708],{"nctId":172,"briefTitle":173,"status":174,"phases":709,"primaryCompletion":176,"completion":176,"start":177,"enrollment":178,"conditions":710,"interventions":711},[48],[180],[182,183,184,185,186,187,188,189,190,191,192,193,194,195,196],{"trials":713,"activeCount":56},[],{"intervention":715,"totalTrials":52,"cells":716},"Zidovudine",{"EARLY_PHASE1":717,"PHASE1":719,"PHASE2":721,"PHASE3":723,"PHASE4":725,"NA":734},{"trials":718,"activeCount":56},[],{"trials":720,"activeCount":56},[],{"trials":722,"activeCount":56},[],{"trials":724,"activeCount":56},[],{"trials":726,"activeCount":56},[727],{"nctId":728,"briefTitle":729,"status":131,"phases":730,"conditions":731,"interventions":733},"NCT00199121","A Pilot Study of Triple NtRTI\u002FNsRTI Therapy in Antiretroviral Naive HIV-1 Infected Patients",[48],[732],"HIV",[715],{"trials":735,"activeCount":56},[],{"intervention":737,"totalTrials":52,"cells":738},"Lactobacillus rhamnosus strain GG ATCC 53103",{"EARLY_PHASE1":739,"PHASE1":741,"PHASE2":743,"PHASE3":745,"PHASE4":747,"NA":757},{"trials":740,"activeCount":56},[],{"trials":742,"activeCount":56},[],{"trials":744,"activeCount":56},[],{"trials":746,"activeCount":56},[],{"trials":748,"activeCount":56},[749],{"nctId":750,"briefTitle":751,"status":174,"phases":752,"completion":599,"start":753,"enrollment":754,"conditions":755,"interventions":756},"NCT00490425","Prevention of Asthma and Allergy by Probiotic Lactobacillus GG",[48],"2002-10",131,[20],[737],{"trials":758,"activeCount":56},[],{"intervention":205,"totalTrials":52,"cells":760},{"EARLY_PHASE1":761,"PHASE1":763,"PHASE2":765,"PHASE3":767,"PHASE4":769,"NA":775},{"trials":762,"activeCount":56},[],{"trials":764,"activeCount":56},[],{"trials":766,"activeCount":56},[],{"trials":768,"activeCount":56},[],{"trials":770,"activeCount":56},[771],{"nctId":198,"briefTitle":199,"status":174,"phases":772,"primaryCompletion":176,"start":177,"enrollment":201,"conditions":773,"interventions":774},[48],[203],[205,182,184,185,186,190,189,188,187,192,191,193,194,206,207],{"trials":776,"activeCount":56},[],{"intervention":206,"totalTrials":52,"cells":778},{"EARLY_PHASE1":779,"PHASE1":781,"PHASE2":783,"PHASE3":785,"PHASE4":787,"NA":793},{"trials":780,"activeCount":56},[],{"trials":782,"activeCount":56},[],{"trials":784,"activeCount":56},[],{"trials":786,"activeCount":56},[],{"trials":788,"activeCount":56},[789],{"nctId":198,"briefTitle":199,"status":174,"phases":790,"primaryCompletion":176,"start":177,"enrollment":201,"conditions":791,"interventions":792},[48],[203],[205,182,184,185,186,190,189,188,187,192,191,193,194,206,207],{"trials":794,"activeCount":56},[],{"intervention":207,"totalTrials":52,"cells":796},{"EARLY_PHASE1":797,"PHASE1":799,"PHASE2":801,"PHASE3":803,"PHASE4":805,"NA":811},{"trials":798,"activeCount":56},[],{"trials":800,"activeCount":56},[],{"trials":802,"activeCount":56},[],{"trials":804,"activeCount":56},[],{"trials":806,"activeCount":56},[807],{"nctId":198,"briefTitle":199,"status":174,"phases":808,"primaryCompletion":176,"start":177,"enrollment":201,"conditions":809,"interventions":810},[48],[203],[205,182,184,185,186,190,189,188,187,192,191,193,194,206,207],{"trials":812,"activeCount":56},[],{"intervention":814,"totalTrials":52,"cells":815},"Somatropin, Clonidine, L-Arginin-Hydrochloride, Estradiol valerate",{"EARLY_PHASE1":816,"PHASE1":818,"PHASE2":820,"PHASE3":822,"PHASE4":824,"NA":837},{"trials":817,"activeCount":56},[],{"trials":819,"activeCount":56},[],{"trials":821,"activeCount":56},[],{"trials":823,"activeCount":56},[],{"trials":825,"activeCount":56},[826],{"nctId":827,"briefTitle":828,"status":131,"phases":829,"primaryCompletion":830,"completion":831,"start":832,"enrollment":833,"conditions":834,"interventions":836},"NCT01052623","Status of Growth Hormone\u002F Insulin-like Growth Factor-1 (GH\u002FIGF-1) Axis and Growth Failure in Ataxia Telangiectasia (AT)",[48],"2011-12","2012-09","2010-01",24,[18,835],"Growth Failure",[814],{"trials":838,"activeCount":56},[],{"intervention":144,"totalTrials":470,"cells":840},{"EARLY_PHASE1":841,"PHASE1":843,"PHASE2":845,"PHASE3":851,"PHASE4":864,"NA":866},{"trials":842,"activeCount":56},[],{"trials":844,"activeCount":56},[],{"trials":846,"activeCount":56},[847],{"nctId":129,"briefTitle":130,"status":131,"phases":848,"start":133,"conditions":849,"interventions":850},[46],[135],[137,120,138,139,140,141,142,143,144,145,146,147,148,149,150,151,152],{"trials":852,"activeCount":56},[853],{"nctId":854,"briefTitle":855,"status":131,"phases":856,"start":857,"enrollment":858,"conditions":859,"interventions":862},"NCT00002793","Chemotherapy Via an Implantable Pump Compared With a Subcutaneous Port for Unresectable Liver Metastases in Patients With Resected Colorectal Cancer",[47],"1991-01",336,[860,861],"Colorectal Cancer","Metastatic Cancer",[863,144],"fluorouracil",{"trials":865,"activeCount":56},[],{"trials":867,"activeCount":56},[],{"intervention":869,"totalTrials":470,"cells":870},"triamcinolone and bevacizumab",{"EARLY_PHASE1":871,"PHASE1":873,"PHASE2":875,"PHASE3":877,"PHASE4":898,"NA":900},{"trials":872,"activeCount":56},[],{"trials":874,"activeCount":56},[],{"trials":876,"activeCount":56},[],{"trials":878,"activeCount":56},[879,889],{"nctId":880,"briefTitle":881,"status":174,"phases":882,"primaryCompletion":883,"completion":884,"start":330,"enrollment":885,"conditions":886,"interventions":888},"NCT00805064","Combined Triple Procedure in Retinal Vein Occlusion (RVO)",[47],"2007-12","2008-11",40,[887],"Retinal Vein Occlusion",[869],{"nctId":890,"briefTitle":891,"status":174,"phases":892,"primaryCompletion":597,"completion":884,"start":893,"enrollment":885,"conditions":894,"interventions":897},"NCT00806169","Combined Triple Therapy in Diabetic Retinopathy (DRP)",[47],"2006-04",[895,896],"Macular Edema","Diabetic Retinopathy",[869],{"trials":899,"activeCount":56},[],{"trials":901,"activeCount":56},[],{"intervention":903,"totalTrials":52,"cells":904},"specific subcutaneous immunotherapy house dust mite allergoid",{"EARLY_PHASE1":905,"PHASE1":907,"PHASE2":909,"PHASE3":911,"PHASE4":923,"NA":925},{"trials":906,"activeCount":56},[],{"trials":908,"activeCount":56},[],{"trials":910,"activeCount":56},[],{"trials":912,"activeCount":56},[913],{"nctId":914,"briefTitle":915,"status":174,"phases":916,"completion":917,"start":918,"enrollment":919,"conditions":920,"interventions":922},"NCT00540150","Compatibility and Immunogenicity of a Short Specific Immunotherapy (SIT) in Contrast to Classic Specific Immunotherapy",[47],"2005-03","2004-05",34,[921],"Immunotherapy",[903],{"trials":924,"activeCount":56},[],{"trials":926,"activeCount":56},[],{"intervention":928,"totalTrials":52,"cells":929},"Vildagliptin",{"EARLY_PHASE1":930,"PHASE1":932,"PHASE2":934,"PHASE3":936,"PHASE4":949,"NA":951},{"trials":931,"activeCount":56},[],{"trials":933,"activeCount":56},[],{"trials":935,"activeCount":56},[],{"trials":937,"activeCount":56},[938],{"nctId":939,"briefTitle":940,"status":941,"phases":942,"primaryCompletion":943,"completion":944,"start":945,"enrollment":56,"conditions":946,"interventions":948},"NCT00936234","Functional Improvement of Progenitor Cells and Endothelial Function by Vildagliptin in Diabetes Mellitus (FINNjA-DM).","WITHDRAWN",[46,47],"2011-09","2013-05","2009-07",[947],"SDF-1 is an Important Cytokine for Neovascularization. Cleavage of SDF-1 is Reduced by DPPIV Inhibitors",[928],{"trials":950,"activeCount":56},[],{"trials":952,"activeCount":56},[],{"intervention":954,"totalTrials":52,"cells":955},"Pantoprazole",{"EARLY_PHASE1":956,"PHASE1":958,"PHASE2":960,"PHASE3":962,"PHASE4":972,"NA":974},{"trials":957,"activeCount":56},[],{"trials":959,"activeCount":56},[],{"trials":961,"activeCount":56},[],{"trials":963,"activeCount":56},[964],{"nctId":965,"briefTitle":966,"status":941,"phases":967,"primaryCompletion":598,"completion":598,"start":968,"enrollment":56,"conditions":969,"interventions":971},"NCT00699361","Influence of Pantoprazole on Human Myocardial Contractility at Patients With Congestive Heart Failure",[47],"2008-08",[970],"Congestive Heart Failure",[954,954],{"trials":973,"activeCount":56},[],{"trials":975,"activeCount":56},[],{"intervention":977,"totalTrials":52,"cells":978},"polyunsatturated fatty acids",{"EARLY_PHASE1":979,"PHASE1":981,"PHASE2":983,"PHASE3":985,"PHASE4":996,"NA":998},{"trials":980,"activeCount":56},[],{"trials":982,"activeCount":56},[],{"trials":984,"activeCount":56},[],{"trials":986,"activeCount":56},[987],{"nctId":988,"briefTitle":989,"status":174,"phases":990,"completion":991,"start":177,"enrollment":992,"conditions":993,"interventions":995},"NCT00380926","Fish Oil and Asthma in House Dust Mite Allergy",[46,47],"2004-11",23,[20,994,29],"Bronchial Inflammation",[977],{"trials":997,"activeCount":56},[],{"trials":999,"activeCount":56},[],{"intervention":863,"totalTrials":52,"cells":1001},{"EARLY_PHASE1":1002,"PHASE1":1004,"PHASE2":1006,"PHASE3":1008,"PHASE4":1014,"NA":1016},{"trials":1003,"activeCount":56},[],{"trials":1005,"activeCount":56},[],{"trials":1007,"activeCount":56},[],{"trials":1009,"activeCount":56},[1010],{"nctId":854,"briefTitle":855,"status":131,"phases":1011,"start":857,"enrollment":858,"conditions":1012,"interventions":1013},[47],[860,861],[863,144],{"trials":1015,"activeCount":56},[],{"trials":1017,"activeCount":56},[],{"intervention":1019,"totalTrials":52,"cells":1020},"C1-Esterase Inhibitor",{"EARLY_PHASE1":1021,"PHASE1":1023,"PHASE2":1025,"PHASE3":1027,"PHASE4":1038,"NA":1040},{"trials":1022,"activeCount":56},[],{"trials":1024,"activeCount":56},[],{"trials":1026,"activeCount":56},[],{"trials":1028,"activeCount":56},[1029],{"nctId":1030,"briefTitle":1031,"status":174,"phases":1032,"primaryCompletion":1033,"completion":1033,"start":1034,"enrollment":833,"conditions":1035,"interventions":1037},"NCT00748202","Berinert P Study of Subcutaneous Versus Intravenous Administration",[47],"2010-12","2008-09",[1036],"Hereditary Angioedema",[1019],{"trials":1039,"activeCount":56},[],{"trials":1041,"activeCount":56},[],{"intervention":1043,"totalTrials":52,"cells":1044},"intracoronary infusion of autologous bone marrow-derived cells",{"EARLY_PHASE1":1045,"PHASE1":1047,"PHASE2":1049,"PHASE3":1051,"PHASE4":1063,"NA":1065},{"trials":1046,"activeCount":56},[],{"trials":1048,"activeCount":56},[],{"trials":1050,"activeCount":56},[],{"trials":1052,"activeCount":56},[1053],{"nctId":1054,"briefTitle":1055,"status":131,"phases":1056,"primaryCompletion":1057,"completion":1058,"start":1059,"enrollment":1060,"conditions":1061,"interventions":1062},"NCT01693042","Compare the Effects of Single Versus Repeated Intracoronary Application of Autologous Bone Marrow-derived Mononuclear Cells on Mortality in Patients With Chronic Post-infarction Heart Failure",[46,47],"2022-11","2025-01","2013-11",81,[15],[1043],{"trials":1064,"activeCount":56},[],{"trials":1066,"activeCount":56},[],{"intervention":1068,"totalTrials":52,"cells":1069},"Montelukast",{"EARLY_PHASE1":1070,"PHASE1":1072,"PHASE2":1074,"PHASE3":1087,"PHASE4":1089,"NA":1091},{"trials":1071,"activeCount":56},[],{"trials":1073,"activeCount":56},[],{"trials":1075,"activeCount":56},[1076],{"nctId":1077,"briefTitle":1078,"status":174,"phases":1079,"primaryCompletion":1080,"completion":1081,"start":1082,"enrollment":1083,"conditions":1084,"interventions":1085},"NCT00543686","Leukotriene Receptor Antagonists or Steroids in Pre-School Asthma",[46],"2009-01","2009-02","2007-08",100,[27],[1068,1086],"Fluticasone",{"trials":1088,"activeCount":56},[],{"trials":1090,"activeCount":56},[],{"trials":1092,"activeCount":56},[],{"intervention":1086,"totalTrials":52,"cells":1094},{"EARLY_PHASE1":1095,"PHASE1":1097,"PHASE2":1099,"PHASE3":1105,"PHASE4":1107,"NA":1109},{"trials":1096,"activeCount":56},[],{"trials":1098,"activeCount":56},[],{"trials":1100,"activeCount":56},[1101],{"nctId":1077,"briefTitle":1078,"status":174,"phases":1102,"primaryCompletion":1080,"completion":1081,"start":1082,"enrollment":1083,"conditions":1103,"interventions":1104},[46],[27],[1068,1086],{"trials":1106,"activeCount":56},[],{"trials":1108,"activeCount":56},[],{"trials":1110,"activeCount":56},[],{"intervention":139,"totalTrials":52,"cells":1112},{"EARLY_PHASE1":1113,"PHASE1":1115,"PHASE2":1117,"PHASE3":1123,"PHASE4":1125,"NA":1127},{"trials":1114,"activeCount":56},[],{"trials":1116,"activeCount":56},[],{"trials":1118,"activeCount":56},[1119],{"nctId":129,"briefTitle":130,"status":131,"phases":1120,"start":133,"conditions":1121,"interventions":1122},[46],[135],[137,120,138,139,140,141,142,143,144,145,146,147,148,149,150,151,152],{"trials":1124,"activeCount":56},[],{"trials":1126,"activeCount":56},[],{"trials":1128,"activeCount":56},[],{"intervention":141,"totalTrials":52,"cells":1130},{"EARLY_PHASE1":1131,"PHASE1":1133,"PHASE2":1135,"PHASE3":1141,"PHASE4":1143,"NA":1145},{"trials":1132,"activeCount":56},[],{"trials":1134,"activeCount":56},[],{"trials":1136,"activeCount":56},[1137],{"nctId":129,"briefTitle":130,"status":131,"phases":1138,"start":133,"conditions":1139,"interventions":1140},[46],[135],[137,120,138,139,140,141,142,143,144,145,146,147,148,149,150,151,152],{"trials":1142,"activeCount":56},[],{"trials":1144,"activeCount":56},[],{"trials":1146,"activeCount":56},[],{"intervention":143,"totalTrials":52,"cells":1148},{"EARLY_PHASE1":1149,"PHASE1":1151,"PHASE2":1153,"PHASE3":1159,"PHASE4":1161,"NA":1163},{"trials":1150,"activeCount":56},[],{"trials":1152,"activeCount":56},[],{"trials":1154,"activeCount":56},[1155],{"nctId":129,"briefTitle":130,"status":131,"phases":1156,"start":133,"conditions":1157,"interventions":1158},[46],[135],[137,120,138,139,140,141,142,143,144,145,146,147,148,149,150,151,152],{"trials":1160,"activeCount":56},[],{"trials":1162,"activeCount":56},[],{"trials":1164,"activeCount":56},[],{"intervention":147,"totalTrials":52,"cells":1166},{"EARLY_PHASE1":1167,"PHASE1":1169,"PHASE2":1171,"PHASE3":1177,"PHASE4":1179,"NA":1181},{"trials":1168,"activeCount":56},[],{"trials":1170,"activeCount":56},[],{"trials":1172,"activeCount":56},[1173],{"nctId":129,"briefTitle":130,"status":131,"phases":1174,"start":133,"conditions":1175,"interventions":1176},[46],[135],[137,120,138,139,140,141,142,143,144,145,146,147,148,149,150,151,152],{"trials":1178,"activeCount":56},[],{"trials":1180,"activeCount":56},[],{"trials":1182,"activeCount":56},[],{"intervention":148,"totalTrials":52,"cells":1184},{"EARLY_PHASE1":1185,"PHASE1":1187,"PHASE2":1189,"PHASE3":1195,"PHASE4":1197,"NA":1199},{"trials":1186,"activeCount":56},[],{"trials":1188,"activeCount":56},[],{"trials":1190,"activeCount":56},[1191],{"nctId":129,"briefTitle":130,"status":131,"phases":1192,"start":133,"conditions":1193,"interventions":1194},[46],[135],[137,120,138,139,140,141,142,143,144,145,146,147,148,149,150,151,152],{"trials":1196,"activeCount":56},[],{"trials":1198,"activeCount":56},[],{"trials":1200,"activeCount":56},[],{"intervention":149,"totalTrials":52,"cells":1202},{"EARLY_PHASE1":1203,"PHASE1":1205,"PHASE2":1207,"PHASE3":1213,"PHASE4":1215,"NA":1217},{"trials":1204,"activeCount":56},[],{"trials":1206,"activeCount":56},[],{"trials":1208,"activeCount":56},[1209],{"nctId":129,"briefTitle":130,"status":131,"phases":1210,"start":133,"conditions":1211,"interventions":1212},[46],[135],[137,120,138,139,140,141,142,143,144,145,146,147,148,149,150,151,152],{"trials":1214,"activeCount":56},[],{"trials":1216,"activeCount":56},[],{"trials":1218,"activeCount":56},[],{"intervention":151,"totalTrials":52,"cells":1220},{"EARLY_PHASE1":1221,"PHASE1":1223,"PHASE2":1225,"PHASE3":1231,"PHASE4":1233,"NA":1235},{"trials":1222,"activeCount":56},[],{"trials":1224,"activeCount":56},[],{"trials":1226,"activeCount":56},[1227],{"nctId":129,"briefTitle":130,"status":131,"phases":1228,"start":133,"conditions":1229,"interventions":1230},[46],[135],[137,120,138,139,140,141,142,143,144,145,146,147,148,149,150,151,152],{"trials":1232,"activeCount":56},[],{"trials":1234,"activeCount":56},[],{"trials":1236,"activeCount":56},[],{"intervention":1238,"totalTrials":52,"cells":1239},"intracoronary infusion of progenitor cells",{"EARLY_PHASE1":1240,"PHASE1":1242,"PHASE2":1244,"PHASE3":1255,"PHASE4":1257,"NA":1259},{"trials":1241,"activeCount":56},[],{"trials":1243,"activeCount":56},[],{"trials":1245,"activeCount":56},[1246],{"nctId":1247,"briefTitle":1248,"status":1249,"phases":1250,"completion":1251,"start":1252,"enrollment":201,"conditions":1253,"interventions":1254},"NCT00289822","Cell Therapy for Coronary Heart Disease","TERMINATED",[46],"2005-01","2002-01",[25],[1238],{"trials":1256,"activeCount":56},[],{"trials":1258,"activeCount":56},[],{"trials":1260,"activeCount":56},[],{"intervention":1262,"totalTrials":52,"cells":1263},"autologous bone marrow-derived progenitor cells",{"EARLY_PHASE1":1264,"PHASE1":1266,"PHASE2":1268,"PHASE3":1280,"PHASE4":1282,"NA":1284},{"trials":1265,"activeCount":56},[],{"trials":1267,"activeCount":56},[],{"trials":1269,"activeCount":56},[1270],{"nctId":1271,"briefTitle":1272,"status":1249,"phases":1273,"primaryCompletion":1274,"completion":1275,"start":1034,"enrollment":1276,"conditions":1277,"interventions":1279},"NCT00711542","Effects of Intracoronary Progenitor Cell Therapy on Coronary Flow Reserve After Acute MI",[45,46],"2014-12","2015-12",31,[25,1278],"Acute Myocardial Infarction",[1262],{"trials":1281,"activeCount":56},[],{"trials":1283,"activeCount":56},[],{"trials":1285,"activeCount":56},[],{"intervention":1287,"totalTrials":52,"cells":1288},"retroviral SF71-gp91phox transduced CD34+ cells",{"EARLY_PHASE1":1289,"PHASE1":1291,"PHASE2":1293,"PHASE3":1303,"PHASE4":1305,"NA":1307},{"trials":1290,"activeCount":56},[],{"trials":1292,"activeCount":56},[],{"trials":1294,"activeCount":56},[1295],{"nctId":1296,"briefTitle":1297,"status":131,"phases":1298,"completion":598,"start":1299,"enrollment":470,"conditions":1300,"interventions":1302},"NCT00564759","Gene Therapy for Chronic Granulomatous Disease",[45,46],"2004-01",[1301],"Granulomatous Disease, Chronic",[1287],{"trials":1304,"activeCount":56},[],{"trials":1306,"activeCount":56},[],{"trials":1308,"activeCount":56},[],{"intervention":1310,"totalTrials":52,"cells":1311},"Panobinostat",{"EARLY_PHASE1":1312,"PHASE1":1314,"PHASE2":1316,"PHASE3":1328,"PHASE4":1330,"NA":1332},{"trials":1313,"activeCount":56},[],{"trials":1315,"activeCount":56},[],{"trials":1317,"activeCount":56},[1318],{"nctId":1319,"briefTitle":1320,"status":131,"phases":1321,"primaryCompletion":1322,"completion":1322,"start":1323,"enrollment":1324,"conditions":1325,"interventions":1327},"NCT01451268","Phase I\u002FII Study With Oral Panobinostat Maintenance Therapy Following Allogeneic Stem Cell Transplantation in Patients With High Risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)",[45,46],"2018-04","2011-01",62,[1326,233],"Myelodysplastic Syndrome",[1310,1310],{"trials":1329,"activeCount":56},[],{"trials":1331,"activeCount":56},[],{"trials":1333,"activeCount":56},[],{"intervention":162,"totalTrials":52,"cells":1335},{"EARLY_PHASE1":1336,"PHASE1":1338,"PHASE2":1340,"PHASE3":1346,"PHASE4":1348,"NA":1350},{"trials":1337,"activeCount":56},[],{"trials":1339,"activeCount":56},[],{"trials":1341,"activeCount":56},[1342],{"nctId":154,"briefTitle":155,"status":131,"phases":1343,"start":157,"conditions":1344,"interventions":1345},[46],[159,160],[162,163,120,164,140,165,146,166,140],{"trials":1347,"activeCount":56},[],{"trials":1349,"activeCount":56},[],{"trials":1351,"activeCount":56},[],{"intervention":164,"totalTrials":52,"cells":1353},{"EARLY_PHASE1":1354,"PHASE1":1356,"PHASE2":1358,"PHASE3":1364,"PHASE4":1366,"NA":1368},{"trials":1355,"activeCount":56},[],{"trials":1357,"activeCount":56},[],{"trials":1359,"activeCount":56},[1360],{"nctId":154,"briefTitle":155,"status":131,"phases":1361,"start":157,"conditions":1362,"interventions":1363},[46],[159,160],[162,163,120,164,140,165,146,166,140],{"trials":1365,"activeCount":56},[],{"trials":1367,"activeCount":56},[],{"trials":1369,"activeCount":56},[],{"intervention":166,"totalTrials":52,"cells":1371},{"EARLY_PHASE1":1372,"PHASE1":1374,"PHASE2":1376,"PHASE3":1382,"PHASE4":1384,"NA":1386},{"trials":1373,"activeCount":56},[],{"trials":1375,"activeCount":56},[],{"trials":1377,"activeCount":56},[1378],{"nctId":154,"briefTitle":155,"status":131,"phases":1379,"start":157,"conditions":1380,"interventions":1381},[46],[159,160],[162,163,120,164,140,165,146,166,140],{"trials":1383,"activeCount":56},[],{"trials":1385,"activeCount":56},[],{"trials":1387,"activeCount":56},[],{"intervention":1389,"totalTrials":52,"cells":1390},"Injection of autovaccine",{"EARLY_PHASE1":1391,"PHASE1":1393,"PHASE2":1404,"PHASE3":1406,"PHASE4":1408,"NA":1410},{"trials":1392,"activeCount":56},[],{"trials":1394,"activeCount":56},[1395],{"nctId":1396,"briefTitle":1397,"status":174,"phases":1398,"primaryCompletion":968,"completion":1033,"start":1399,"enrollment":1400,"conditions":1401,"interventions":1403},"NCT00677209","The Effect of Autologous Autovaccine in Patients With Allergy on House-dust-mite",[45],"2006-07",8,[1402],"Allergens, House Dust Mites",[1389],{"trials":1405,"activeCount":56},[],{"trials":1407,"activeCount":56},[],{"trials":1409,"activeCount":56},[],{"trials":1411,"activeCount":56},[],{"intervention":335,"totalTrials":470,"cells":1413},{"EARLY_PHASE1":1414,"PHASE1":1416,"PHASE2":1418,"PHASE3":1420,"PHASE4":1422,"NA":1428},{"trials":1415,"activeCount":56},[],{"trials":1417,"activeCount":56},[],{"trials":1419,"activeCount":56},[],{"trials":1421,"activeCount":56},[],{"trials":1423,"activeCount":56},[1424],{"nctId":325,"briefTitle":326,"status":174,"phases":1425,"primaryCompletion":328,"completion":329,"start":330,"enrollment":331,"conditions":1426,"interventions":1427},[48],[333],[140,335,336],{"trials":1429,"activeCount":56},[1430],{"nctId":1431,"briefTitle":1432,"status":174,"phases":1433,"primaryCompletion":1434,"completion":1033,"start":1435,"enrollment":1436,"conditions":1437,"interventions":1439},"NCT00802906","Bevacizumab Versus Micropulse in Central Serous Chorioretinopathy (CSC)",[49],"2010-11","2007-05",12,[1438],"Central Serous Chorioretinopathy",[335],{"intervention":1441,"totalTrials":52,"cells":1442},"Granisetron Hydrochloride",{"EARLY_PHASE1":1443,"PHASE1":1445,"PHASE2":1447,"PHASE3":1449,"PHASE4":1451,"NA":1453},{"trials":1444,"activeCount":56},[],{"trials":1446,"activeCount":56},[],{"trials":1448,"activeCount":56},[],{"trials":1450,"activeCount":56},[],{"trials":1452,"activeCount":56},[],{"trials":1454,"activeCount":56},[1455],{"nctId":1456,"briefTitle":1457,"status":174,"phases":1458,"primaryCompletion":1459,"completion":1460,"start":1461,"enrollment":1462,"conditions":1463,"interventions":1466},"NCT03318536","Effect of Granisetron on Usage of Sympathomimetics During Caesarean Section",[],"2017-11-01","2018-02-01","2017-10-05",240,[1464,1465],"Hypotension","Cesarean Section Complications",[1441,1467],"No Granisetron",{"intervention":1467,"totalTrials":52,"cells":1469},{"EARLY_PHASE1":1470,"PHASE1":1472,"PHASE2":1474,"PHASE3":1476,"PHASE4":1478,"NA":1480},{"trials":1471,"activeCount":56},[],{"trials":1473,"activeCount":56},[],{"trials":1475,"activeCount":56},[],{"trials":1477,"activeCount":56},[],{"trials":1479,"activeCount":56},[],{"trials":1481,"activeCount":56},[1482],{"nctId":1456,"briefTitle":1457,"status":174,"phases":1483,"primaryCompletion":1459,"completion":1460,"start":1461,"enrollment":1462,"conditions":1484,"interventions":1485},[],[1464,1465],[1441,1467],{"intervention":1487,"totalTrials":52,"cells":1488},"autologous bone marrow-derived cells",{"EARLY_PHASE1":1489,"PHASE1":1491,"PHASE2":1493,"PHASE3":1495,"PHASE4":1497,"NA":1499},{"trials":1490,"activeCount":56},[],{"trials":1492,"activeCount":56},[],{"trials":1494,"activeCount":56},[],{"trials":1496,"activeCount":56},[],{"trials":1498,"activeCount":56},[],{"trials":1500,"activeCount":56},[1501],{"nctId":1502,"briefTitle":1503,"status":131,"phases":1504,"primaryCompletion":1505,"completion":1506,"start":1507,"enrollment":1508,"conditions":1509,"interventions":1512},"NCT00962364","Long-term Evaluation of Patients Receiving Bone Marrow-derived Cell Administration for Heart Disease",[],"2020-12","2021-12","2001-10",1500,[1278,1510,1511,15],"Ischemic Cardiomyopathy","Dilated Cardiomyopathy",[1487],{"intervention":1514,"totalTrials":52,"cells":1515},"house dust mite and alternaria allergen bronchial challenge",{"EARLY_PHASE1":1516,"PHASE1":1518,"PHASE2":1520,"PHASE3":1522,"PHASE4":1524,"NA":1526},{"trials":1517,"activeCount":56},[],{"trials":1519,"activeCount":56},[],{"trials":1521,"activeCount":56},[],{"trials":1523,"activeCount":56},[],{"trials":1525,"activeCount":56},[],{"trials":1527,"activeCount":56},[1528],{"nctId":1529,"briefTitle":1530,"status":174,"phases":1531,"primaryCompletion":830,"completion":1532,"start":1323,"enrollment":1533,"conditions":1534,"interventions":1536},"NCT01134757","Safety of Bronchial Allergen Challenge and Predictors for Positive Reaction.",[49],"2012-10",425,[29,1535],"Bronchial Hyperresponsiveness",[1514]]